DDA Platform Launches Customized in Vitro Assay Testing from Target Discovery to Expression in Order to Accelerate Drug Discovery

Creative Bioarray's recently announced in vitro screening service provides customized in vitro assays from target discovery to expression to gain insight into in vivo translation and ultimately clinical applications.

DDA platform, the mature division of Creative Bioarray whose mission is developing unique technologies that provide global customers with high quality products and services to facilitate the investigation of life science researches, solve complex analytical challenges, and increase laboratory productivity, solve complex analytical challenges, and increase laboratory productivity.

Creative Bioarray's recently announced in vitro screening service provides customized in vitro assays from target discovery to expression to gain insight into in vivo translation and ultimately clinical applications. The cell biology experts in Creative Bioarray have created a highly replicable archived cell bank containing more than 200 cancer cell lines. For each cell line, Creative Bioarray has validated animal xenograft models for later in vivo pharmacological studies, thereby significantly reducing the time required from cell-based assays to in vivo pharmacology.

Since protein kinases are involved in pathological conditions such as cancer, neurological diseases, inflammatory diseases and metabolic problems, they represent one of the most promising drug targets. Classical methods for analyzing kinase activity include quantifying phosphate transfer by detecting the production of phosphorylated products or changes in the ratio of ATP to ADP. In order to assist in kinase drug discovery efforts, Creative Bioarray provides high-quality, time-saving, and cost-effective kinase solutions for analytical development, high-throughput screening (HTS) and selective analysis.

Creative Bioarray has decades of experience in providing kinase products and services to meet various drug discovery research needs and is capable of providing high-quality active proteins for internal research and drug discovery screening. It can also customize protein production, assay development and kinase selective analysis for customers.

As a professionally managed facility, Creative Bioarray has well-trained and experienced staff, advanced equipment and a large number of compound libraries. Combining these functions with a centralized knowledge base can increase cost-effectiveness and productivity in the continuous fight against the disease. Creative Bioarray scientists have rich expertise in multiple therapeutic areas, target types, assay formats, compound management and data analysis, and are committed to helping our customers determine and advance their biochemical and cell-based assay discovery research plans. Creative Bioarray also provides compound screening services in single compound format or compressed format for client libraries, and stores a copy for multiple screening activities.

In addition, Creative Bioarray's high content screening platform has extensive experience in phenotypic analysis, from functional analysis (such as inhibition of phagocytosis and quantification of cytoskeletal changes) to transcriptional reporter gene regulation (such as activation of insulin promoter activity). It can provide more than 100 kinds of HCS analysis for customers to choose and can customize any test to meet the strict needs of customers.

“As we expand our ability to combine high-content analysis with high-throughput screening, we are moving from traditional target-centric biochemical analysis methods to phenotypic and genomic methods to dynamically study disease targets and determine the design and development of new methods of therapeutic molecules.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “We focus on standard and customized in vitro tests, and we provide customers with cost-effective, high-quality, reproducible data and flexible solutions with fast turnaround time.”

About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Phone: 1 6316197922
Website: https://dda.creative-bioarray.com/

Release ID: 88983287